At one point in his remarks accepting the 2009 Leadership in Personalized Medicine award from the Personalized Medicine Coalition (PMC), Brook Byers of the VC firm Kleiner Perkins Caufield & Byers asked the audience gathered at Harvard University's Harvard Medical School: "Where is the economic stimulus money for personalized medicine?" With so many billions flowing from the US government through the National Institutes of Health and a consistent buzz around comparative effectiveness research (CER), it's a question he and others are beginning to ask in earnest.
"I think there are program-ready studies that could have benefited in the context of the ARRA [American Recovery and Reinvestment Act of 2009] funds," says M. Kathleen Behrens, PhD, of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?